FDA approves new meds for rheumatoid arthritis, ADHD
diciembre 19, 2012
The U.S. Food and Drug Administration recently gave the go-ahead to two new drugs, Xeljanz and Quillivant XR, to treat rheumatoid arthritis and Attention Deficit Hyperactivity Disorder, respectively, the manufacturing companies announced in separate statements.
burbuja de chat0 Comentarios
visibilidad6113 Views
Proveedor de contenido de Dow Jones/Factiva desde 2014.
¡Suscríbase a nuestro podcast Dollars & Sense!
NIMB EN LAS REDES SOCIALES